Shopping Cart

Your shopping cart is currently empty

Lamivudine

Name: Lamivudine
Brand: TargetMol
SKU: T0682
Price: 50 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T0682Cas No. 134678-17-4

Alias GR109714X, BCH-189

Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Lamivudine

🥰Excellent

Purity: 99.56%

Catalog No. T0682Alias GR109714X, BCH-189Cas No. 134678-17-4

Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$53	In Stock	In Stock
100 mg	$79	In Stock	In Stock
500 mg	$189	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$50	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.56%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
In vivo	Lamivudine exhibits selective inhibitory activity against deoxycytidine kinase, an unusual substrate for the non-natural L-isomer of dNTPs preferred by HBV polymerase. The anti-HBV activity of PCV is attributed to the broad substrate specificity of deoxycytidine kinase and an unusual substrate preference of HBV polymerase for the non-natural L-conformation of dNTPs. The anti-HBV efficacy of PCV appears to rely on multiple factors, including optimal phosphorylation (sufficient for antiviral activity but not cytotoxicity), the extended intracellular half-life of PCV-TP, and the ability of PCV-TP to inhibit the initiation of HBV RT as well as its RT and DNA polymerase activities. Combined use of Lamivudine and Cidofovir synergistically inhibits replication of duck hepatitis B virus and is more effective in reducing the persistent covalently closed circular (CCC) DNA form of DHBV than when used separately. In PBMCs, Lamivudine inhibits HIV-1 p24 antigen production with ED50s ranging from 0.07 μM to 0.2 μM.
Synonyms	GR109714X, BCH-189

Chemical Properties

Molecular Weight	229.26
Formula	C₈H₁₁N₃O₃S
Cas No.	134678-17-4
Smiles	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1
Relative Density.	1.73 g/cm3 (Predicted)

Storage & Solubility Information

Storage

store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 240 mg/mL (1046.85 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: 42 mg/mL (183.2 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (21.81 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	4.3619 mL	21.8093 mL	43.6186 mL	218.0930 mL
5 mM	0.8724 mL	4.3619 mL	8.7237 mL	43.6186 mL
10 mM	0.4362 mL	2.1809 mL	4.3619 mL	21.8093 mL
20 mM	0.2181 mL	1.0905 mL	2.1809 mL	10.9046 mL
50 mM	0.0872 mL	0.4362 mL	0.8724 mL	4.3619 mL
100 mM	0.0436 mL	0.2181 mL	0.4362 mL	2.1809 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc